[Immune thrombocytopenia: From pathogenesis to treatment]

Area of Science:

• Immunology
• Hematology
• Autoimmune Diseases

Background:

• Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by peripheral platelet destruction and impaired platelet production.
• The pathogenesis involves a humoral immune response, including T follicular helper cell stimulation of B cells, leading to antiplatelet antibody production and platelet phagocytosis by splenic macrophages.

Purpose of the Study:

• To elucidate the complex pathogenesis of Immune thrombocytopenia (ITP).
• To understand the limitations of current treatments like rituximab.
• To explore novel therapeutic strategies for ITP.

Main Methods:

• Review of current understanding of ITP pathogenesis.
• Analysis of immune response pathways involved in ITP.
• Evaluation of emerging therapeutic targets and mechanisms.

Main Results:

• ITP pathogenesis is increasingly understood, involving T follicular helper cells, B cells, and antiplatelet antibodies.
• The inefficiency of treatments like rituximab is partly explained by the complex immune mechanisms.
• New therapeutic avenues are emerging, targeting Fcγ receptor signaling and neonatal Fc receptor (FcRn).

Conclusions:

• Advances in understanding ITP pathogenesis have opened new therapeutic avenues.
• Targeting Fcγ receptor signaling (e.g., Syk inhibitors) and enhancing autoantibody clearance (e.g., FcRn inhibitors) represent promising strategies for ITP treatment.